昌吉男科好医院排名(昌吉割包皮手术痛) (今日更新中)

LAS VEGAS, the United States, Jan. 12 (Xinhua) -- NVIDIA, the computer chip manufacturer best known for its high performance graphics processors, is looking to make further inroads with the automobile industry by integrating its new Tegra 3 mobile processors in upcoming vehicle models.At the 2012 International Consumer Electronics Show (CES), NVIDIA and Audi announced that all models from the German auto manufacturer in 2013 will use Tegra 3 quad-core processors to power their in-car digital systems.These processors, which are traditionally found in smartphones and tablets, will support the vehicle's digital systems at lower energy rates and also allow for shorter lead times in getting concepts to market.In addition to powering infotainment systems that allow for web browsing and Google Earth integrations, they will also give automakers the ability to replace traditional dashboards with instrument cluster systems, or digital dashboards."By leveraging technology from the very latest smartphones and tablets, Audi is leading the market with innovations that enhance safety and make driving more enjoyable," said Ricky Hudi, the company's chief executive engineer, at Audi's official conference at CES.For Audi, this means that they will be able to offer cars like the next-generation A3 model beginning in 2013, which features an integrated touchpad system and mounted monitor with the ability to render 3D imaging. Current 2012 Audi vehicles house the Tegra 2 processor."It's a natural progression with people getting so accustomed to mobile and expecting it from your automobiles as well. Partnering really closely with automotive OEMs enable us to help them realize the driver experience they're looking to deliver," said Phillip Hughes, NVIDIA's director of automotive sales and business development, in an interview with Xinhua.In addition to Audi, Tesla and Lamborghini will also be including the newest NVIDIA Tegra 3 processor in upcoming models. At this year's CES, Lamborghini is showcasing the Lamborghini Aventador, a nearly 700 horsepower vehicle with the capability of going from 0 to 60 miles per mile in less than five seconds."NVIDIA technology is enabling us to do more with our vehicles and gives our cars the ability to have the technology you'd expect from a car like this," said Kelly Snyder, an event manager with Lamborghini, to Xinhua. The retail price point for the Lamborghini Aventador starts at 382,000 U.S. dollars.More than just powering the car's digital experiences, however, integrating NVIDIA's processors will help the auto manufacturer build better cars by reducing the power to weight ratio that is a key consideration in manufacturing higher performing cars."By moving elements like the odometer to a digital dashboard platform, it reduces the power to weight ratio that is so critical to the design and manufacturing of automobiles like the Lamborghini," explained Snyder.NVIDIA also expects that the integration of these processors will bring the development cycle of the automotive industry up to speed with the consumer electronics industry through Virtual Computing Modules (VCMs) powered by the Tegra 3. These VCMs allow auto manufacturers to quickly prototype and ship consumer technology innovations to automobiles, reducing a development lifecycle that once took seven years, to roughly a year."At the end of the day, our goal is to help automotive OEMs bridge the gap between OEM and consumer technology," said Hughes.

ADDIS ABABA, Nov. 2 (Xinhua) -- Ethiopia will host the 13th World Congress on Public Health (WCPH) in April 2012, the Ethiopian Public Health Association (EPHA) said on Wednesday.The meeting will be held on April 23-27 under the theme: "Moving towards Global Health Equity- Opportunities and Treats".Speaking on the 22nd annual meeting of EPHA held here on Wednesday EPHA President Tewabech Bishaw said about 3,000 participants, including public health students from all over the world are expected to take part in the meeting.He said that preparations are well underway to successfully conduct the meeting.

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

来源：资阳报